MCID: PRP030
MIFTS: 55

Purpura

Categories: Blood diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Purpura

Summaries for Purpura

MalaCards based summary: Purpura, also known as purpuric disorder, is related to thrombotic thrombocytopenic purpura and henoch-schoenlein purpura, and has symptoms including hemoptysis, pruritus and flushing. An important gene associated with Purpura is ADAMTS13 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13), and among its related pathways/superpathways are Disease and TGF-Beta Pathway. The drugs Rituximab and Alemtuzumab have been mentioned in the context of this disorder. Affiliated tissues include skin, bone marrow and t cells, and related phenotypes are homeostasis/metabolism and nervous system

Wikipedia: 75 Purpura (/ˈpɜːrpjʊərə/) is a condition of red or purple discolored spots on the skin that do not blanch... more...

Related Diseases for Purpura

Diseases related to Purpura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1937)
# Related Disease Score Top Affiliating Genes
1 thrombotic thrombocytopenic purpura 32.8 VWF THBD SERPINC1 GP1BA F3 ADAMTS13
2 henoch-schoenlein purpura 32.8 TNF IL6 CRP CD79A
3 hyperglobulinemic purpura 32.6 TNFSF13B IFNG
4 purpura fulminans 32.3 THBD SERPINC1 PROC F3 F2 ADAMTS13
5 evans' syndrome 32.1 THPO MPL ADAMTS13
6 protein c deficiency 31.9 THBD SERPINC1 PROC F2
7 thrombocytopenic purpura, autoimmune 31.8 THPO PF4 MPL ITGB3 ITGA2B GP1BA
8 protein s deficiency 31.7 THBD SERPINC1 PROC F3 F2
9 hypersensitivity vasculitis 31.5 TNF IL6 F2 CRP CD79A
10 fetal and neonatal alloimmune thrombocytopenia 31.5 ITGB3 ITGA2B GP1BA
11 thrombocytopenia due to platelet alloimmunization 31.3 VWF TNFSF13B THPO PF4 MPL ITGB3
12 amegakaryocytic thrombocytopenia, congenital 31.3 THPO MPL ITGA2B GP1BA
13 acute kidney failure 31.3 IL6 F2 ADAMTS13
14 rubella 31.2 TNF IL6 IL10 IFNG
15 vasculitis 31.2 VWF TNFSF13B TNF THBD IL6 IL10
16 viral infectious disease 31.1 TNF IL6 IL10 IFNG
17 inflammatory bowel disease 1 31.1 TNF IL6 IL10
18 hemolytic-uremic syndrome 31.1 VWF THBD SERPINC1 F3 F2 ADAMTS13
19 mumps 31.0 TNF IL6 IL10 IFNG
20 proliferative glomerulonephritis 31.0 TNFSF13B IFNG CD79A
21 hemophilia a 30.9 VWF F3 F2
22 meningococcemia 30.9 THBD SERPINC1
23 dermatitis 30.9 TNF IL6 IL10 IFNG
24 glomerulonephritis 30.9 TNF IL6 IL10 CRP CD79A
25 factor viii deficiency 30.9 VWF SERPINC1 F3 F2
26 allergic disease 30.8 TNF IL6 IL10 IFNG
27 human cytomegalovirus infection 30.8 TNF IL6 IL10
28 dengue disease 30.8 TNF IL6 IL10
29 ileitis 30.8 TNF IL6 IL10
30 cryoglobulinemia 30.8 TNFSF13B TNF IL6 IL10 IFNG CD79A
31 graft-versus-host disease 30.8 TNF IL10 IFNG
32 disseminated intravascular coagulation 30.7 VWF TNF THBD SERPINC1 IL6 IL10
33 macroglobulinemia 30.7 TNFSF13B TNF IL6
34 hemolytic uremic syndrome, atypical 1 30.7 VWF THBD F3 F2 CRP ADAMTS13
35 rheumatic fever 30.7 TNF IL6 IL10 IFNG
36 autoimmune hepatitis 30.7 TNF IL10 IFNG F2
37 retinal detachment 30.7 TNF IL6 IL10 IFNG
38 diarrhea 30.7 VWF TNF IL6 IL10 IFNG ADAMTS13
39 exanthem 30.6 TNF IL6 IL10 IFNG F3 F2
40 duodenal ulcer 30.6 TNF IL6 IL10
41 fasciitis 30.6 TNF IL6 IFNG
42 polyarteritis nodosa 30.6 TNF IL6 CRP
43 myasthenia gravis 30.6 TNFSF13B TNF IL6 IL10 IFNG
44 pancreatitis 30.6 TNF IL6 IL10 CRP
45 churg-strauss syndrome 30.6 TNF THBD IL10
46 aplastic anemia 30.6 TNF THPO MPL IL6 IL10 IFNG
47 strongyloidiasis 30.6 IL10 IFNG CD79A
48 hepatitis a 30.6 TNF IL10 IFNG F3 F2
49 factor vii deficiency 30.6 SERPINC1 F3 F2
50 acute graft versus host disease 30.5 TNF IL10 IFNG

Graphical network of the top 20 diseases related to Purpura:



Diseases related to Purpura

Symptoms & Phenotypes for Purpura

UMLS symptoms related to Purpura:


hemoptysis; pruritus; flushing; icterus; petechiae of skin; skin manifestations; integumentary system signs and symptoms

GenomeRNAi Phenotypes related to Purpura according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.17 ADAMTS13 CD79A CRP F2 F3 GP1BA
2 no effect GR00402-S-2 10.17 ADAMTS13 CD79A CRP F2 F3 GP1BA

MGI Mouse Phenotypes related to Purpura:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 ADAMTS13 CD79A CRP F2 F3 GP1BA
2 nervous system MP:0003631 10.32 CD79A F2 F3 IFNG IL10 IL6
3 cellular MP:0005384 10.24 CD79A F2 F3 GP1BA IFNG IL10
4 immune system MP:0005387 10.21 ADAMTS13 CD79A CRP F2 F3 IFNG
5 muscle MP:0005369 10.15 F2 F3 IFNG IL10 IL6 ITGB3
6 liver/biliary system MP:0005370 10.13 CD79A IFNG IL10 IL6 ITGB3 PROC
7 cardiovascular system MP:0005385 10.13 CRP F2 F3 IFNG IL10 IL6
8 embryo MP:0005380 10.09 F2 F3 IFNG IL10 ITGA2B ITGB3
9 neoplasm MP:0002006 10.07 CD79A F3 IFNG IL10 IL6 ITGB3
10 digestive/alimentary MP:0005381 10.06 F2 IFNG IL10 IL6 ITGA2B ITGB3
11 hematopoietic system MP:0005397 9.93 ADAMTS13 CD79A F2 F3 GP1BA IFNG
12 respiratory system MP:0005388 9.85 F2 F3 IFNG IL10 IL6 ITGB3
13 mortality/aging MP:0010768 9.5 ADAMTS13 CD79A F2 F3 IFNG IL10

Drugs & Therapeutics for Purpura

Drugs for Purpura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 238)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rituximab Approved Phase 4 174722-31-7
2
Alemtuzumab Approved, Investigational Phase 4 216503-57-0
3
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
4
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
5
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6 9578005
6
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
7
Clarithromycin Approved Phase 4 81103-11-9 84029
8
Azathioprine Approved Phase 4 446-86-6 2265
9
Morphine Approved, Investigational Phase 4 57-27-2 5288826
10
Hydroxychloroquine Approved Phase 4 118-42-3 3652
11
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
12
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
13
Glycyrrhizic acid Approved, Experimental Phase 4 1405-86-3 3495 14982
14
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
15
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
16
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
17
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
18
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
19
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
20
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
21
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
22
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453
23
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
24
3,4-Dihydroxycinnamic Acid Experimental, Investigational Phase 4 331-39-5, 501-16-6 689043
25
Enoxolone Investigational Phase 4 471-53-4 3230 18526330 10114
26
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
27 Antineoplastic Agents, Immunological Phase 4
28 Calcium, Dietary Phase 4
29 Vitamins Phase 4
30 Trace Elements Phase 4
31 Micronutrients Phase 4
32 Calciferol Phase 4
33 Vasoconstrictor Agents Phase 4
34 Antimitotic Agents Phase 4
35 Tubulin Modulators Phase 4
36 Cytochrome P-450 Enzyme Inhibitors Phase 4
37 Anti-Ulcer Agents Phase 4
38 Antacids Phase 4
39 Cytochrome P-450 CYP3A Inhibitors Phase 4
40 Antiprotozoal Agents Phase 4
41 Antiparasitic Agents Phase 4
42 Antimalarials Phase 4
43 Arnica Phase 4
44 Retinol palmitate Phase 4
45 Autoantibodies Phase 4
46
Methylprednisolone Acetate Phase 4 584547
47
Calcium Nutraceutical Phase 4 7440-70-2 271
48
Metronidazole Approved Phase 3 443-48-1, 69198-10-3 4173
49
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
50
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3

Interventional clinical trials:

(show top 50) (show all 450)
# Name Status NCT ID Phase Drugs
1 Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura Unknown status NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
2 Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia in Pediatrics Unknown status NCT04102033 Phase 4 Eltrombopag
3 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Unknown status NCT03771378 Phase 4 rhTPO;eltrombopag
4 A Multicenter Randomized Open-label Clinical Trial of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP Unknown status NCT04094805 Phase 4 Rocaltrol;Dexamethasone
5 A Multicenter, Randomized, Open-label Study To Compare The Efficacy And Safety Of Eltrombopag Combining Rituximab With Eltrombopag In Adult ITP Patients Unknown status NCT04518475 Phase 4 eltrombopag combining rituximab;eltrombopag
6 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
7 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
8 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab
9 A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
10 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
11 An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis Completed NCT01390649 Phase 4
12 High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
13 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
14 Off-label Use of Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis: Effectiveness and Safety Completed NCT03222687 Phase 4 tacrolimus;prednisone
15 Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment Completed NCT03784898 Phase 4
16 Randomized, Double-Blind, Contralateral, Controlled Study to Assess the Efficacy of DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Mature Skin of the Forearms and Hands Completed NCT01910831 Phase 4 DerMend Moisturizing Bruise Formula;Non-active placebo control
17 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Completed NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
18 Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) Completed NCT04089267 Phase 4 TPO
19 Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim Completed NCT02760251 Phase 4 romiplostim
20 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
21 Short-course High-dose Prednisone and Dexamethasone in Children With Immune A Multicenter, Randomized Controlled Study of Thrombocytopenia Recruiting NCT05522465 Phase 4 Prednisone;Dexamethasone
22 Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Recruiting NCT03866798 Phase 4
23 Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim Recruiting NCT04638829 Phase 4 Avatrombopag Oral Tablet
24 A Multicenter, Randomized Controlled Study of Two Regimens of Intravenous Immune Globulin in the Treatment of Newly Diagnosed Immune Thrombocytopenia in Children Recruiting NCT05520892 Phase 4 intravenous immunoglobulin
25 A Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03998982 Phase 4 Glycyrrhetinic Acid;Dexamethasone
26 Efficacy and Safety of Eltrombopag Combined With Low-dose Rituximab in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to First-line Treatment: a Prospective, Open-label, Nonrandomized, Multicenter Clinical Trial Recruiting NCT04915482 Phase 4 Combined use of eltrombopag with low-dose rituximab;The best available therapy
27 A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency) Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
28 Efficacy and Safety of Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to Eltrombopag or Herombopag Treatment: a Single-center, Prospective, One-arm Clinical Trial Recruiting NCT04993885 Phase 4 Avatrombopag
29 The Efficacy and Safety of Bortezomib as First-line Treatment for Acquired Thrombotic Thrombocytopenic Purpura Not yet recruiting NCT05135442 Phase 4 Bortezomib Injection
30 Comparing the Efficacy and Safety of Optimized rhTPO Treatment Versus Eltrombopag Treatment in Previously Treated Primary Immune Thrombocytopenia Patients: A Multicenter Randomized Open-label Trial Not yet recruiting NCT05583838 Phase 4 rhTPO;Eltrombopag
31 Efficacy and Safety of TPO Receptor Agonists as First-line Drugs in the Treatment of Newly Diagnosed Elderly ITP Patients in China-an Open Label Study Not yet recruiting NCT05311930 Phase 4 2.5mg/d Hetrombopag
32 Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura Withdrawn NCT01754545 Phase 4 Octaplas infusion and placebo (group 1);Octaplas infusion and placebo (group 2)
33 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
34 A Multicenter Prospective Randomized Study of Dexamethasone Combined With Decitabine Versus Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Unknown status NCT03252457 Phase 3 Decitabine;Dexamethasone
35 Efficacy of Helicobacter Pylori Eradication for the Treatment of Chronic or Persistent Immune Thrombocytopenic Purpura Patients With Moderate Thrombocytopenia: Multicenter Prospective Randomized Phase 3 Study Unknown status NCT03177629 Phase 3 treatment : H. pylori eradication
36 Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes Unknown status NCT02877212 Phase 3 Eltrombopag
37 A Multicenter Prospective Randomized Study of Rituximab Combined With Bortezomib Versus Rituximab in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Unknown status NCT03443570 Phase 3 Rituximab;Bortezomib
38 A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia Unknown status NCT01805648 Phase 3 rhTPO
39 Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Unknown status NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
40 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial Unknown status NCT02270801 Phase 3 rhTPO
41 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
42 Proof of Concept; A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia Unknown status NCT03520049 Phase 3 Oseltamivir;Placebo
43 Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
44 A Multicenter Clinical Study of Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia Unknown status NCT03492515 Phase 3 recombinant human thrombopoietin;Platelet Concentrate
45 A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
46 A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP) Completed NCT01444417 Phase 3 Romiplostim;Placebo
47 A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 Versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Completed NCT00415532 Phase 3 Medical Standard of Care for ITP
48 Clinical Trial to Evaluate the Efficacy and the Safety of IGIV3I Grifols 10% (Human Intravenous Immunoglobulin) in Patients Diagnosed With Immune Thrombocytopenic Purpura Completed NCT00699140 Phase 3
49 Predictive Value of the Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura of Children and Adults. Completed NCT04070599 Phase 3
50 Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)-An Extension Study of Eltrombopag in Subjects, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study TRA108109 (NCT00540423)-<Phase III Study> Completed NCT00828750 Phase 3 Eltrombopag oral tablets

Search NIH Clinical Center for Purpura

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Epoprostenol
Epoprostenol Sodium

Cochrane evidence based reviews: purpura

Genetic Tests for Purpura

Anatomical Context for Purpura

Organs/tissues related to Purpura:

MalaCards : Skin, Bone Marrow, T Cells, Spleen, Bone, B Cells, Liver

Publications for Purpura

Articles related to Purpura:

(show top 50) (show all 24547)
# Title Authors PMID Year
1
Tissue deposits of IgA-binding streptococcal M proteins in IgA nephropathy and Henoch-Schonlein purpura. 53 62
20056836 2010
2
Henoch-Schönlein nephritis associated with streptococcal infection and persistent hypocomplementemia: a case report. 53 62
20181224 2010
3
[Henoch-Shönlein purpura]. 53 62
19345173 2009
4
Vasculitic IgA nephropathy: prognosis and outcome. 53 62
19342865 2009
5
Childhood Henoch-Schonlein nephritis: a multivariate analysis of clinical features and renal morphology at disease onset. 53 62
19377254 2009
6
Familial clusturing of Henoch-Schönlein purpura or IgA nephropathy: genetic background or environmental triggers? 53 62
19067882 2008
7
IgA nephropathy and Henoch-Schönlein purpura nephritis. 53 62
18332712 2008
8
The diagnostic value of IgA deposition in Henoch-Schönlein purpura. 53 62
18304186 2008
9
Splenic peliosis in the course of IgA nephropathy. 53 62
17885767 2007
10
Renal involvement in Henoch-Schönlein purpura: a multivariate analysis of initial prognostic factors. 53 62
17551657 2007
11
Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schönlein-Henoch purpura nephritis. 53 62
17699418 2007
12
Thrombopoietin and interleukin-6 levels in Henoch-Schönlein purpura. 53 62
17164950 2006
13
Fatal relapse of thrombotic thrombocytopaenic purpura after cardiac surgery in patient with congenital absence of vWF-cleaving protease activity. 53 62
16421154 2006
14
Thrombotic thrombocytopaenic purpura in HIV-infected patients. 53 62
16105187 2005
15
[Effect of danshao granule on serum superoxide dismutase activity and malonyldialdehyde content in children with Henoch-Schonlein purpura nephritis]. 53 62
14714360 2003
16
A perspective on the measurement of ADAMTS13 in thrombotic thrombocytopaenic purpura. 53 62
12656756 2003
17
Immunoglobulin A-associated lymphocytic vasculopathy: a clinicopathologic study of eight patients. 53 62
12453297 2002
18
Acute glomerulonephritis. 53 62
10798062 1999
19
IgA nephropathy--human disease and animal model. 53 62
9154653 1997
20
Schönlein-Henoch purpura in adult patients. Predictive factors for IgA glomerulonephritis in a retrospective study of 57 cases. 53 62
9126006 1997
21
Hypergammaglobulinemic purpura associated with Sjögren's syndrome and chronic C type hepatitis. 53 62
9046734 1997
22
Inherited prethrombotic disorders and infectious purpura. 53 62
8822583 1996
23
Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. 53 62
8639762 1996
24
IgA-associated renal diseases. 53 62
8744534 1996
25
Serum anti-streptococcal IgA, IgG and IgM antibodies in IgA-associated diseases. 53 62
8503268 1993
26
Heavy and light chain composition of serum IgA and IgA rheumatoid factor in Henoch-Schönlein purpura. 53 62
1445457 1992
27
Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. 53 62
1430582 1992
28
Regional variation in C4 phenotype in patients with IgA nephropathy. 53 62
2329414 1990
29
[Schönlein-Henoch purpura and IgA nephropathy. A common pathogenetic cause?]. 53 62
2327670 1990
30
Inherited ADAMTS13 mutations associated with Thrombotic Thrombocytopenic Purpura: a short review and update. 62
36281781 2023
31
Hematologic and Oncologic Emergencies. 62
36415070 2023
32
Maternal morbidity and mortality in pregnant/postpartum women with suspected HELLP syndrome identifiable as probable thrombotic thrombocytopenic purpura or atypical hemolytic uremic syndrome by high LDH to AST ratio. 62
35301713 2022
33
[Thrombotic microangiopathies in surgical intensive care medicine with special consideration of atypical hemolytic uremic syndrome]. 62
36454255 2022
34
Differentiating and Managing Rare Thrombotic Microangiopathies During Pregnancy and Postpartum. 62
36455925 2022
35
[[Translated articleNonpalpable Purpura in a Patient With Sjögren Syndrome. 62
36464009 2022
36
Effectiveness of lymphoplasmapheresis compared with therapeutic plasma exchange for thrombotic thrombocytopenic purpura: a retrospective evaluation. 62
35068383 2022
37
Therapeutic plasma exchange in gastric signet ring cell carcinoma presenting as microangiopathic hemolytic anemia: A rare case report. 62
36125111 2022
38
Clinical features and neurological outcomes in pediatric immune-mediated thrombotic thrombocytopenic purpura: A report from a large pediatric hematology center. 62
36151977 2022
39
Face mask-induced purpura: another unexpected effect of COVID era. 62
35771119 2022
40
Cutaneous manifestations of antineutrophil cytoplasmic antibody-associated vasculitis (AAV): a concise review with emphasis on clinical and histopathologic correlation. 62
35599359 2022
41
The characteristics of patients with COVID-19-associated pediatric vasculitis: an international, multicenter study. 62
36457245 2022
42
Clinical analysis of 99 children with Henoch-Schönlein purpura complicated with overt gastrointestinal bleeding. 62
35941339 2022
43
[Refractory thrombotic thrombocytopenic purpura]. 62
36194294 2022
44
A new treatment strategy for thrombotic thrombocytopenic purpura in developing countries: A single dose rituximab-contained regimen. 62
36272335 2022
45
Usefulness of arterial spin labeling in identifying status epilepticus secondary to acquired thrombotic thrombocytopenic purpura. 62
36425942 2022
46
Immune thrombotic thrombocytopenic purpura plasmas induce calcium- and IgG-dependent endothelial activation: correlations with disease severity. 62
36453103 2022
47
Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study. 62
36138517 2022
48
Mechanisms of ADAMTS13 regulation. 62
36074019 2022
49
IgA Vasculitis With Concurrent ANCA-Positivity in the Setting of Bacterial Endocarditis. 62
36413453 2022
50
Panton-Valentine leucocidin-producing Staphylococcus aureus: a clinical review. 62
36040400 2022

Variations for Purpura

Expression for Purpura

Search GEO for disease gene expression data for Purpura.

Pathways for Purpura

Pathways related to Purpura according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 VWF ITGB3 ITGA2B IL6 IL10 GP1BA
2
Show member pathways
13.46 TNFSF13B TNF THPO MPL ITGB3 ITGA2B
3
Show member pathways
13.35 IL10 IL6 ITGA2B ITGB3 PF4 THPO
4
Show member pathways
13.1 VWF THPO THBD SERPINC1 PROC PF4
5
Show member pathways
12.77 THBD SERPINC1 PROC F3 F2
6
Show member pathways
12.58 ITGB3 ITGA2B IFNG F2 CRP
7
Show member pathways
12.55 TNF IL6 IL10 IFNG F2
8 12.5 TNFSF13B TNF MPL IL10 IFNG CD79A
9
Show member pathways
12.43 F2 F3 GP1BA PF4 PROC SERPINC1
10
Show member pathways
12.33 SERPINC1 PROC IL6 F2
11
Show member pathways
12.19 THBD PROC PF4 ITGB3 F2
12 12.06 TNF IL6 IL10 IFNG
13 11.95 TNFSF13B TNF IL6 IFNG
14
Show member pathways
11.88 TNF IL6 IL10 IFNG
15 11.8 VWF ITGB3 F3
16 11.75 TNF IL10 IFNG
17
Show member pathways
11.75 TNF IFNG F3
18 11.72 IFNG IL10 IL6
19
Show member pathways
11.68 F2 GP1BA ITGA2B ITGB3 MPL THPO
20 11.67 IL6 IL10 IFNG
21 11.67 TNF THBD IL6 IL10 IFNG
22 11.65 TNF IL6 IL10 IFNG CRP CD79A
23 11.64 IL10 IL6 TNF TNFSF13B
24
Show member pathways
11.63 TNF IL6 IFNG
25 11.62 TNF IL6 IL10
26
Show member pathways
11.61 TNF IL6 IL10 IFNG
27 11.53 TNF IL6 IFNG
28 11.5 F2 ITGA2B ITGB3 VWF
29 11.49 TNF IL6 IL10
30 11.46 IFNG IL6 TNF
31 11.39 TNF THPO MPL ITGB3 ITGA2B IL6
32
Show member pathways
11.34 TNF IL10 IFNG
33 11.32 TNF IL6 IL10
34 11.27 TNF IL6 IFNG
35 11.24 TNF IL6 IL10 IFNG
36 11.19 TNF IL6 IL10 IFNG
37 11.02 TNF IL6 CRP
38 11 PF4 ITGB3 ITGA2B IL10 F3 F2
39 10.94 TNFSF13B TNF THPO PF4 ITGB3 ITGA2B
40
Show member pathways
10.34 TNF IL6

GO Terms for Purpura

Cellular components related to Purpura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.27 ADAMTS13 CRP F2 F3 IFNG IL10
2 cell surface GO:0009986 10.16 TNF THBD MPL ITGB3 ITGA2B GP1BA
3 external side of plasma membrane GO:0009897 9.86 CD79A F2 F3 GP1BA ITGA2B ITGB3
4 extracellular space GO:0005615 9.83 VWF TNFSF13B TNF THPO THBD SERPINC1
5 serine-type endopeptidase complex GO:1905370 9.8 THBD PROC F2

Biological processes related to Purpura according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.3 TNF PF4 ITGB3 IL6 IFNG F3
2 platelet aggregation GO:0070527 10.08 MPL ITGB3 GP1BA
3 positive regulation of chemokine production GO:0032722 10.06 TNF IL6 IFNG
4 cellular response to lipopolysaccharide GO:0071222 10.06 ADAMTS13 IL10 IL6 PF4 THPO TNF
5 immune response GO:0006955 10.04 TNFSF13B TNF PF4 IL6 IL10 IFNG
6 acute-phase response GO:0006953 10.02 IL6 F2 CRP
7 liver regeneration GO:0097421 10.01 IL10 IL6 TNF
8 response to activity GO:0014823 10.01 TNF ITGB3 IL6 IL10
9 platelet activation GO:0030168 10 ADAMTS13 F2 GP1BA IL6 ITGB3 PF4
10 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 9.97 TNF IL6 IL10 F2
11 negative regulation of MHC class II biosynthetic process GO:0045347 9.89 PF4 IL10
12 blood coagulation GO:0007596 9.89 VWF THBD SERPINC1 PROC ITGB3 GP1BA
13 negative regulation of cytokine production involved in immune response GO:0002719 9.88 TNF IL10
14 thrombopoietin-mediated signaling pathway GO:0038163 9.86 THPO MPL
15 negative regulation of lipid storage GO:0010888 9.86 TNF ITGB3 IL6 CRP
16 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.83 TNF IFNG
17 regulation of blood coagulation GO:0030193 9.83 F2 GP1BA SERPINC1
18 positive regulation of nitrogen compound metabolic process GO:0051173 9.81 TNF IFNG
19 positive regulation of vitamin D biosynthetic process GO:0060557 9.8 TNF IFNG
20 chronic inflammatory response to antigenic stimulus GO:0002439 9.78 TNF IL10
21 hemostasis GO:0007599 9.28 VWF THBD SERPINC1 PROC GP1BA F3

Molecular functions related to Purpura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.65 VWF TNF SERPINC1 ITGB3 F3
2 cytokine activity GO:0005125 9.44 TNFSF13B TNF THPO PF4 IL6 IL10

Sources for Purpura

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....